advertisement
Abstract #19811 Published in IGR 9-4
Pathologically activated therapeutics for neuroprotection
Lipton SANature Reviews Neuroscience 2007; 8: 803-808
Many drugs that have been developed to treat neurodegenerative diseases fail to gain approval for clinical use because they are not well tolerated in humans. In this article, I describe a series of strategies for the development of neuroprotective therapeutics that are both effective and well tolerated. These strategies are based on the principle that drugs should be activated by the pathological state that they are intended to inhibit. This approach has already met with success, and has led to the development of the potentially neuroprotective drug memantine, an N-methyl-D-aspartate (NMDA)-type and glutamate receptor antagonist.
Dr. S.A. Lipton, Burnham Institute for Medical Research, Salk Institute for Biological Studies, University of California at San Diego, 10901 North Torrey Pines Road, San Diego, CA 29,037, USA. slipton@burnham.org
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
